Actionable news
All posts from Actionable news

Prospectuses and communications, business combinations


Filed by: TriVascular Technologies, Inc.

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12 of the

Securities Exchange Act of 1934

Subject Company: Tri Vascular Technologies, Inc.

Commission File No.: 001-36419

TriVascular Technologies, Inc. Reports Third Quarter Financial Results

Santa Rosa, Calif., November 9, 2015 TriVascular Technologies, Inc. (NASDAQ:TRIV), manufacturer of the Ovation ® Abdominal Stent Graft platform, today reported financial results for the third quarter ended September 30, 2015.

Recent Accomplishments:

We are pleased with our domestic and international performance in the third quarter which demonstrates continued adoption of the Ovation platform said President and Chief Executive Officer, Chris Chavez. As announced on October 26, 2015, TriVascular and Endologix, Inc. signed a definitive merger agreement to form a combined company focused on providing physicians with innovative new technologies for the treatment of patients with AAA. We look forward to bringing together our combined expertise for the benefit of our customers, patients, employees and stockholders. We believe, following the closing of the merger currently expected to be in early 2016, the combined capabilities and differentiated technologies of both companies will allow us to more effectively advance our goal to improve and expand EVAR safely for more patients.

Third Quarter Financial Results

Revenue for the three months ended September 30, 2015 increased 20.0% to $9.5 million, from $7.9 million in the same period of the prior year. Geographically, revenue in the United States was $6.5 million, an increase of 20.3% from the three months ended September 30, 2014. International revenue totaled $3.0 million, an increase of 19.4% from the three months ended September 30, 2014. On a constant currency basis international and worldwide revenue increased 30.6% and 23.4%, respectively, in the quarter.

Gross margin for the third quarter of 2015 was 63.5%, up from 57.2% in the three months ended September 30, 2014. The increase in gross margin was primarily due to spreading manufacturing overhead costs over higher production volumes.

Operating expenses for the third quarter of 2015 were $17.4 million, an increase of 5% compared to the third quarter of 2014. The increase in operating expenses was driven primarily by an increase in selling, marketing and general and administrative expenses.

Loss from operations for the third quarter of 2015 was $11.4 million, compared to $12.1 million for the third quarter of 2014. Net loss for the third quarter of 2015 was $13.6 million, compared to $13.9 million for the third quarter of 2014. Adjusted EBITDA, a non-GAAP measure, was a loss of $10.1 million for the third quarter of 2015 compared to $11.4 million in the third quarter of 2014.

Cash and cash equivalents and short term investments were $50.0 million as of September 30, 2015.

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures of Adjusted EBITDA and of constant currency revenue growth percentage. We evaluate our results of operations on an as reported and a constant currency basis. The constant currency presentation, which is a non-GAAP measure, excludes the impact of fluctuations in foreign currency exchange rates. We believe presenting constant currency information provides valuable supplemental information regarding our results of operations, consistent with how we evaluate our performance. We calculate constant currency percentages by converting our prior-period local currency financial results using the current period exchange rates and comparing these adjusted amounts to our current period reported results. We define EBITDA as net loss plus interest expense, income tax expense, and depreciation and amortization. We define Adjusted...